Literature DB >> 23434386

Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis.

Manabu Ato1, Yoshimasa Takahashi, Hideki Fujii, Shu-ichi Hashimoto, Tomohiro Kaji, Shigeyuki Itamura, Yoshinobu Horiuchi, Yoshichika Arakawa, Masato Tashiro, Toshitada Takemori.   

Abstract

Infection with single strand RNA (ssRNA) viruses, such as influenza A virus, is known to induce protective acquired immune responses, including the production of neutralizing antibodies. Vaccination also causes a reduction in the number of peripheral blood leukocytes (PBL) shortly after inoculation, a result which may have undesirable adverse effects. The cellular mechanisms for this response have not been elucidated so far. Here we report that formalin-inactivated influenza A whole virus vaccine (whole virion) induces a significant decrease in PBL in mice 5-16 h after administration, whereas an ether-split vaccine (HA split) made from the same influenza virus strain does not induce a similar loss of PBL. Concordant with this reduction in the number of PBL, a rapidly induced and massive production of interferon (IFN)-α is observed when mice are injected with whole virion, but not with HA split vaccines. The role of Toll-like receptors (TLR), which are involved in signal transduction of influenza virus, and the subsequent induction of IFNα were confirmed using mice lacking TLR7, MyD-88, or IFNα/β receptor. We further demonstrated that the observed PBL loss is caused by apoptosis in an IFNα-dependent manner, and not by leukocyte redistribution due to chemokine signaling failure. These findings indicate that RNA-encapsulated whole virion vaccines can rapidly induce a loss of leukocytes from peripheral blood by apoptosis, which may modulate the subsequent immune response.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23434386     DOI: 10.1016/j.vaccine.2013.02.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors.

Authors:  William E O'Gorman; Huang Huang; Yu-Ling Wei; Kara L Davis; Michael D Leipold; Sean C Bendall; Brian A Kidd; Cornelia L Dekker; Holden T Maecker; Yueh-Hsiu Chien; Mark M Davis
Journal:  Vaccine       Date:  2014-09-06       Impact factor: 3.641

2.  FcγRIIB prevents inflammatory type I IFN production from plasmacytoid dendritic cells during a viral memory response.

Authors:  Marcella Flores; Claude Chew; Kevin Tyan; Wu Qing Huang; Aliasger Salem; Raphael Clynes
Journal:  J Immunol       Date:  2015-03-27       Impact factor: 5.426

3.  Modeling for influenza vaccines and adjuvants profile for safety prediction system using gene expression profiling and statistical tools.

Authors:  Eita Sasaki; Haruka Momose; Yuki Hiradate; Keiko Furuhata; Mamiko Takai; Hideki Asanuma; Ken J Ishii; Takuo Mizukami; Isao Hamaguchi
Journal:  PLoS One       Date:  2018-02-06       Impact factor: 3.240

4.  Changes of urine metabolite profiles are induced by inactivated influenza vaccine inoculations in mice.

Authors:  Eita Sasaki; Hideki Kusunoki; Haruka Momose; Keiko Furuhata; Kazuo Hosoda; Kaori Wakamatsu; Takuo Mizukami; Isao Hamaguchi
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

Review 5.  Sweeten PAMPs: Role of Sugar Complexed PAMPs in Innate Immunity and Vaccine Biology.

Authors:  Ranjeet Singh Mahla; Madhava C Reddy; D Vijaya Raghava Prasad; Himanshu Kumar
Journal:  Front Immunol       Date:  2013-09-02       Impact factor: 7.561

6.  System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test.

Authors:  Takuo Mizukami; Haruka Momose; Madoka Kuramitsu; Kazuya Takizawa; Kumiko Araki; Keiko Furuhata; Ken J Ishii; Isao Hamaguchi; Kazunari Yamaguchi
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

7.  Development of a preclinical humanized mouse model to evaluate acute toxicity of an influenza vaccine.

Authors:  Eita Sasaki; Haruka Momose; Yuki Hiradate; Keiko Furuhata; Takuo Mizukami; Isao Hamaguchi
Journal:  Oncotarget       Date:  2018-05-25

8.  Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization.

Authors:  Eita Sasaki; Hideki Asanuma; Haruka Momose; Keiko Furuhata; Takuo Mizukami; Isao Hamaguchi
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.